Strong Revenue Growth
Sanara MedTech's surgical team achieved net revenue of $26.3 million in Q3 2025, marking a 22% year-over-year growth, driven by soft tissue repair products.
Improved Profitability
The company reported a $1 million improvement in net income from continuing operations and a $2.3 million increase in adjusted EBITDA on net revenue growth of $4.7 million.
Expansion of Distributor Network
Sanara expanded its network from 300 to over 400 contracted distributors over the last 12 months, enhancing its market reach.
Clinical Evidence and New Product Initiatives
Two studies on CellerateRX were published in peer-reviewed journals, supporting its efficacy in complex surgical procedures. Progress was also made with the OsStic product under the BMI partnership.